CalciMedica (CALC) Return on Capital Employed (2020 - 2026)
CalciMedica's (CALC) quarterly Return on Capital Employed came in at 384.22% in Q1 2026, down 24655.0% YoY from N/an in Q1 2025, and down 73.99% on a QoQ basis from 220.83% in Q4 2025.
CalciMedica (CALC) Return on Capital Employed (2020 - 2026) Analysis & Trends
CalciMedica (CALC) has 7 years of Return on Capital Employed data on file, last reported at 384.22% in Q1 2026.
- Quarterly Return on Capital Employed fell 24655.0% year-over-year to 384.22% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 384.22% (down 24655.0% YoY) and the FY2025 annual result came in at 179.09%, up 1761.0% from the prior year.
- Return on Capital Employed retreated to 384.22% in Q1 2026, from 220.83% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 42.97% in Q2 2022 to a low of 508.29% in Q1 2023.
- A 5-year average of 184.06% and a median of 150.51% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 46377 bps — and 2024, when it jumped 36841 bps.
- Tracing CALC's Return on Capital Employed over 5 years: stood at 72.51% in 2022, then plunged by 426 bps to 381.25% in 2023, then jumped by 56 bps to 169.03% in 2024, then tumbled by 31 bps to 220.83% in 2025, then plunged by 74 bps to 384.22% in 2026.
- The last three Return on Capital Employed figures came in at 384.22% (Q1 2026), 220.83% (Q4 2025), and 187.06% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | CalciMedica | 9.93 Mn | -8.69 Mn | - | -185.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -185.75% |
| Mar 31, 2026 | -384.22% |
| Dec 31, 2025 | -220.83% |
| Sep 30, 2025 | -187.06% |
| Jun 30, 2025 | -133.57% |
| Mar 31, 2025 | -137.67% |
| Dec 31, 2024 | -169.03% |
| Sep 30, 2024 | -150.51% |
| Jun 30, 2024 | -106.29% |
| Mar 31, 2024 | -139.87% |
| Dec 31, 2023 | -381.25% |
| Sep 30, 2023 | -256.71% |
| Jun 30, 2023 | -150.71% |
| Mar 31, 2023 | -508.29% |
| Dec 31, 2022 | -72.51% |
| Sep 30, 2022 | -43.09% |
| Jun 30, 2022 | -42.97% |
| Mar 31, 2022 | -44.51% |
| Dec 31, 2021 | -52.24% |
| Sep 30, 2021 | -48.41% |